Cellectis
430 East 29th Street / New York, NY
8 rue de la Croix Jarry / 75013 Paris
2500 Sumner Boulevard / Raleigh, NC
United States
Website: http://www.cellectis.com/
69 articles about Cellectis
-
Cellectis secures a €40 million credit facility from the European Investment Bank to support its Research, Development and Innovation activities
12/28/2022
Cellectis, a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced that it has entered into a €40 million credit facility agreement with the European Investment Bank .
-
Cellectis Announces First Dosing of a Patient with its In-house Manufactured Product Candidate UCART22 for the treatment of r/r B-cell ALL
12/22/2022
Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that for the first time, a patient was dosed in the United States with its in-house manufactured product candidate UCART22, and completed the 28 day DLT period on December 14th, 2022, without complication.
-
Cellectis Announces Positive Preliminary Clinical Data for UCART22 in ALL and UCART123 in AML
12/13/2022
Cellectis S.A. today will host a live webcast reviewing updated clinical data on its Phase 1/2a BALLI-01 clinical trial (evaluating UCART22) and on its Phase 1 AMELI-01 clinical trial (evaluating UCART123) that were presented in an oral session on December 12, 2022 at the 64th Annual Meeting of the American Society of Hematology (ASH).
-
Cellectis to Host a Live Webcast and Provide a Company Update on December 13, 2022
12/1/2022
Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, will host a live webcast to review the Company’s clinical data on the AMELI-01 study (evaluating UCART123) presented at the ASH Annual Meeting, and provide a Company update, on December 13, 2022.
-
Cellectis Publishes Manuscript in Frontiers Bioengineering and Biotechnology Unveiling Efficient Multitool/Multiplex Gene Engineering combining TALEN® and TALE Base Editors (TALE-BE)
11/10/2022
Cellectis published a manuscript in Frontiers Bioengineering and Biotechnology demonstrating the feasibility of efficient multiplex gene engineering using a combination of two different molecular tools: Cellectis’ TALEN® gene editing technology and a TALE-BE.
-
Cellectis Presents Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Overcoming Key Challenges of Targeting Solid Tumors at SITC 2022
11/10/2022
Cellectis today announced that preclinical data will be presented on TALEN®-edited smart CAR T-cells overcoming key challenges of targeting solid tumors at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting.
-
Cellectis to Showcase Clinical Data from AMELI-01 and Preclinical Data from UCARTCS1 at ASH 2022
11/3/2022
Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced the release of two abstracts, which were accepted for presentation at the 64th American Society of Hematology (ASH) Annual Meeting taking place from December 10 to 13, 2022.
-
Cellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Months 2022
11/3/2022
Cellectis (Euronext Growth: ALCLS – Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop potentially life-saving cell and gene therapies, announced its results for the three-month and nine-month periods ending September 30, 2022.
-
Cellectis to Report Third Quarter 2022 Financial Results
10/27/2022
Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS) today announced that it will report financial results for the third quarter ended September 30th, 2022, on Thursday, November 3rd, 2022, after the close of the US market.
-
Cellectis Presents Data on Two TALEN®-based Gene Therapy Preclinical Programs for Patients with Sickle Cell Disease and Mucopolysaccharidosis type I at ESGCT 2022
10/11/2022
Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS) announced today that the Company will present both an oral and poster at the European Society of Gene and Cell Therapy’s (ESGCT) 29th Congress, to be held in Edinburgh from October 11-14, 2022.
-
Cellectis to Present Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Supporting Improved Solid Tumor Targeting at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
10/5/2022
Cellectis announced today that pre-clinical data on TALEN ® -edited smart CAR T-cells to overcome key challenges of targeting solid tumors, will be presented at the Society for Immunotherapy of Cancer’s 37th Annual Meeting (SITC 2022), to be held in Boston, M.A.
-
Cellectis Appoints Mark Frattini, M.D., Ph.D. as Chief Medical Officer
9/28/2022
Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the appointment of Mark Frattini, M.D., Ph.D., as Chief Medical Officer, effective immediately.
-
Cellectis Announces Participation in Four Upcoming Investor Conferences in September 2022 - Sep 01, 2022
9/1/2022
Cellectis, a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced that management plans to participate in four upcoming investor conferences.
-
The FDA has had a busy week, accepting drug applications, approving clinical trials and granting various special designations for Gamida Cell, Cellectis, Scynexis & more.
-
Cellectis Provides Business Update and Reports Financial Results for Second Quarter 2022
8/4/2022
Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today provided business update and announced its results for the six-month period ending June 30, 2022.
-
Cellectis Receives IND clearance for UCART20x22, its First in-house Manufactured Product Candidate for the Treatment of B-cell Malignancies
8/1/2022
Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared Cellectis’ Investigational New Drug (IND) application to initiate a Phase 1/2a clinical trial of UCART20x22 for patients with relapsed or refractory Non-Hodgkin Lymphoma (r/r NHL).
-
Cellectis to Report Second Quarter 2022 Financial Results
7/28/2022
Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the second quarter ended June 30th , 2022, on Thursday, August 4th , 2022, after the close of the US market.
-
Cellectis shared how its novel immune-evasive universal CAR T cells may potentially deploy large amounts of T-cell product candidates to target multiple malignancies.
-
Cellectis Publishes Article in Nature Communications Unveiling Novel Immune-Evasive Universal Allogeneic CAR T-cells with Potential for Improved Persistence
6/30/2022
Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today publishes research data on its novel immune-evasive universal CAR T-cells in Nature Communications.
-
Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 28, 2022
6/28/2022
Cellectis S.A. held its Annual Shareholders’ General Meeting (Euronext Growth: ALCLS – Nasdaq: CLLS) on June 28, 2022 at its head office in Paris, France.